San Francisco startup Structure Therapeutics can be focusing on an oral, the moment-day by day GLP-one drug identified as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June any time a mid-phase study confirmed typical weight loss of all around 6% and it strategies to start out A different mid-stage trial to the top of the calendar